Sara Farina

Dr. Sara Farina

Dipartimento di Sciente della vita e Salute Pubblica, Sezione di Igiene, Università Cattolica del Sacro Cuore, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
SFSara Farina
Sara Farina
ASAlessandra Sabatelli
Alessandra Sabatelli
SBStefania Boccia
Stefania Boccia
GSGiovanni Scambia
Giovanni Scambia
Environmental and lifestyle factors significantly contribute to gynecological cancers. The risk of ovarian cancer, one the most lethal gynecological cancer, is associated with obesity, poor dietary habits, and environmental pollutants, exacerbating hormonal imbalances, inflammation, and oxidative stress. Protective factors, such as the Mediterranean diet and oral contraceptives, modulate risk by reducing ovulatory cycles, particularly in genetically predisposed women. Uterine cancer is associated with metabolic factors, with obesity driving hormonal disruptions and systemic inflammation. Physical inactivity and diets rich in animal fats increase the risk of endometrial cancer, along with air pollution and microbiome imbalances contribute to endometrial carcinogenesis. Cervical cancer is primarily driven by persistent high‐risk HPV infection, with smoking enhancing viral persistence and oncogenesis. Nutritional deficiencies in antioxidants and folate weaken immune defenses, while vaginal and gut microbiome dysbiosis fosters neoplastic progression. Vulvar and vaginal cancers, though less common, share risk factors such as obesity, smoking, and occupational exposures, disrupting immune responses and epithelial integrity. Microbial imbalances exacerbate these malignancies, creating a pro‐inflammatory microenvironment. The interplay between modifiable factors and genetic predisposition, including high‐penetrance mutations and polygenic risk scores, highlights the complexity complexity of prevention of gynecological cancers. Epigenetic mechanisms, such as DNA methylation and histone modifications, further modulate susceptibility and tumor progression, influenced by environmental and lifestyle exposures. In addition, promoting and supporting healthy lifestyle changes, including smoking cessation, increased physical activity, and a balanced diet, are crucial for improving long‐term outcomes and quality of life in gynecological cancer survivors. Addressing these factors through personalized prevention, leveraging predictive models incorporating genetics and modifiable risks, enables tailored lifestyle interventions and avoidance of environmental exposures. Combined with equitable public health initiatives, these strategies have the potential to reduce the burden of gynecological cancers and improve women's health globally.

20 November 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
SFSara Farina
Sara Farina
AMAlessandra Maio
Alessandra Maio
MGMaria Rosaria Gualano
Maria Rosaria Gualano
WRWalter Ricciardi
Walter Ricciardi
LVLeonardo Villani
Leonardo Villani
Background/Objectives: Vaccination is one of the most effective public health interventions, preventing millions of deaths globally each year. However, vaccine hesitancy, driven by misinformation and reduced disease risk perception, has led to declining vaccination rates and the resurgence of vaccine-preventable diseases (VPDs) in Europe. In response to this, countries have implemented various strategies, including mandatory and recommended vaccination programs. The objective of this study is to map the current European landscape of pediatric vaccination policies, and the variations that have occurred in the last decade. Methods: This rapid review was conducted on PubMed, Google, and the European Centre for Disease Prevention and Control website, to collect all vaccination schedules in EU/EEA countries in 2024 and all documents focusing on the introduction of mandatory vaccines during the last decade. Results: As of 2024, 13 countries had at least one mandatory pediatric vaccination, with France, Hungary, and Latvia requiring all but one vaccine. In contrast, 17 countries had no mandatory vaccinations, relying only on recommendations. Between 2014 and 2024, six countries (Croatia, France, Germany, Hungary, Italy, and Poland) introduced or extended mandatory vaccinations. Conclusions: European vaccination policies show significant variation. Effective programs depend on robust healthcare systems, public trust, and adaptable strategies to address vaccine hesitancy and the resurgence of VPDs.

13 January 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SFSara Farina
Sara Farina
TOTommaso Osti
Tommaso Osti
LRLuigi Russo
Luigi Russo
AMAlessandra Maio
Alessandra Maio
NSNicolò Scarsi
Nicolò Scarsi
SBStefania Boccia
Stefania Boccia
Introduction: Personalised prevention offers a promising tool to reduce the impact of non-communicable diseases, which represent a growing health burden worldwide. However, to support the adoption of this innovation it is needed to clarify the current state of available evidence in this area. This work aims to provide an overview of recent publications on personalised prevention for chronic conditions. Materials and methods: A scoping review of scientific literature from Medline, Scopus, Web of Science and grey literature was conducted. Eligible articles included prospective primary studies and clinical practice directives on personalised preventive approaches for chronic diseases published between January 2017 to December 2023. The review followed Arksey-O’Malley guidelines and PRISMA-ScR checklist. Results: We identified 121 publications including 60 primary cohort studies and 61 clinical practice directives. We extracted 249 personalised preventive approaches, 27% in primary prevention, 27% in secondary prevention, and 46% in tertiary prevention. In primary prevention, 50% of the 67 approaches were from cohort studies, mainly targeting cardiovascular diseases, and 50% from directives primarily focused on cancer. Secondary prevention included 66 approaches, 73% from directives mainly concerning breast cancer. Tertiary prevention included 116 approaches, evenly distributed among the two publication types and focusing mostly on cancer and cardiovascular diseases. Lastly, tertiary prevention is the most represented level of prevention both in primary research studies and directives (54% and 41% respectively). Conclusions: Our study highlights a significant focus on personalised prevention in oncology in the past few years, with numerous recently issued clinical practice directives. We identified substantial original research in personalised primary prevention of cardiovascular diseases, indicating growing interest in the field. However, the distribution of primary studies and directives across the three preventive levels anticipate challenges in generating evidence of clinical utility in primary and secondary prevention, with most approaches falling under tertiary prevention.

4 December 2025 in Public Health
Verified
Journal Article
Open access
AGAngelica Valz Gris
Angelica Valz Gris
SFSara Farina
Sara Farina
MPMartina Porcelli
Martina Porcelli
MPMatteo Di Pumpo
Matteo Di Pumpo
AFAngelo Farina
Angelo Farina
MGMaria Rosaria Gualano
Maria Rosaria Gualano
To synthesize evidence from meta-analyses of randomized controlled trials (RCTs) evaluating interventions aimed at improving polypharmacy management in older adults, with a focus on key clinical outcomes including mortality, hospitalizations, and falls. Umbrella review. We conducted an umbrella review of systematic reviews with meta-analyses of RCTs assessing interventions to optimize polypharmacy in elderly populations across healthcare settings. Eligible interventions included medication reviews, deprescribing strategies, and educational or behavioral approaches targeting medication appropriateness, reduction, or adherence. Searches were performed in Pubmed, Cochrane and Web of Science up to September 2024. Study selection, data extraction, and quality assessment, performed using AMSTAR2 and GRADE, were independently conducted by multiple reviewers. The protocol was prospectively registered on the Open Science Framework, and reporting followed the PRIOR checklist. Six articles including 21 meta-analyses, encompassing 110 primary RCTs, were included. Medication reviews focused on deprescribing were associated with reduced mortality in community settings but not in hospitals. Behavioral and mixed educational-behavioral interventions appeared most effective in reducing hospitalizations, particularly in community populations. Medication reviews in hospital settings showed only modest effects, and no intervention significantly reduced fall risk. The overall certainty of evidence was low due to heterogeneity, small-study effects, and publication bias. Evidence on interventions to manage polypharmacy in older adults remains limited and inconsistent. Tailored, patient-centered strategies may offer greater benefit, but higher-quality and standardized trials are needed to strengthen the evidence base and guide public health strategies in aging populations.

12 August 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
AMAlessandra Maio
Alessandra Maio
SFSara Farina
Sara Farina
TOTommaso Osti
Tommaso Osti
SGSalvatore Di Grande
Salvatore Di Grande
RPRoberta Pastorino
Roberta Pastorino
SBStefania Boccia
Stefania Boccia
Introduction: Non-communicable diseases represent a significant burden on global healthcare, necessitating innovative strategies to enhance prevention and management. Personalized prevention, an emerging approach leveraging omics data to tailor interventions, holds promise for improving risk stratification, early diagnosis, and preventive strategies. To gain insights on the latest funding investments in this field, we mapped European Commission (EC)-funded research projects on personalized prevention for non-communicable diseases.Materials and methods: We carried out a scoping review of gray literature sources, following the Arksey and O’Malley framework, combined with expert consultations to validate findings and address data gaps. Inclusion criteria focused on projects that began or were ongoing in 2024 (from January 1st to December 31st).Results: We identified 67 projects supported by a total amount of €511.9 million from EC funding. The main programs include Horizon Europe, Horizon 2020, and EU4Health. In particular, Horizon Europe funds 51% of these projects, with a total allocation of €253.8 million, 44% of which specifically address cancer. Overall, 48% of the projects target cancer, followed by neurological and psychiatric diseases (15%), cardiovascular diseases (13%), metabolic disorders (9%), and other NCDs (16%). In terms of prevention levels, 21% of the projects are dedicated to primary prevention, 41% to secondary prevention, and 38% to tertiary prevention.Conclusion: The EC’s investment in personalized prevention is predominantly directed toward cancer, reflecting the goals of the Cancer Mission and the European Beating Cancer Plan. Research on tertiary prevention remains less prominent, likely due to its already established clinical applications, while the emphasis on primary and secondary prevention is reassuring, considering the current gaps in clinical utility evidence in these areas.

MSMaria Lucia Specchia
Maria Lucia Specchia
APANDREA DI PILLA
ANDREA DI PILLA
Maria Antonietta GambacortaMaria Antonietta Gambacorta
Maria Antonietta Gambacorta
AFAlessandro Filippella
Alessandro Filippella
FBFlavia Beccia
Flavia Beccia
Giampaolo TortoraGiampaolo Tortora
Giampaolo Tortora
Colorectal cancer (RC) is the third most common cancer, with an increasing incidence in recent years. Digital health solutions supporting multidisciplinary tumor boards (MTBs) could improve positive outcomes for RC patients. This paper describes the implementation process of a digital solution within the RC-MTB and its impact analysis in the context of the Fondazione Policlinico ‘A. Gemelli’ in Italy. Adopting a two-phase methodological approach, the first phase qualitatively describes each phase of the implementation of the IT platform, while the second phase quantitatively describes the analysis of the impact of the IT platform. Descriptive and inferential analyses were performed for all variables, with a p-value < 0.05 being considered statistically significant. The implementation of the platform allowed more healthcare professionals to attend meetings and resulted in a decrease in patients sent to the RC-MTB for re-staging and further diagnostic investigations and an increase in patients sent to the RC-MTB for treatment strategies. The results could be attributed to the facilitated access to the platform remotely for specialists, partly compensating for the restrictions imposed by the COVID-19 pandemic, as well as to the integration of the platform into the hospital’s IT system. Furthermore, the early involvement of healthcare professionals in the process of customizing the platform to the specific needs of the RC-MTB may have facilitated its use and contributed to the encouraging quantitative results.